Novel Therapeutic Perspectives in the Management of DLBCL:
The Role of Antibody-Drug Conjugates and Bispecific Antibodies
Post-Test/Evaluation
Exit Survey
Questions marked with a
*
are required
30%
Contact Information
First Name
Last Name
Email Address
Credentials/Degree (MD, DO, RN, etc.)
Date of Participation
Month
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
Day
01
02
03
04
05
06
07
08
09
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
Year
2018
2019
2020
2021
2022
2023
2024
2025
Are you a Physician?
Yes
No
The payload in antibody drug conjugates is:
A. A monoclonal antibody
B. A small-molecule chemotherapy
C. A checkpoint inhibitor
D. A hormonal agent
Which of the following is approved for B-cell lymphoma?
A. Glofitamab
B. Mosunetuzumab
C. Epcortimab
D. Polatuzumab vedotin
67-year-old woman diagnosed w DLBCL, GCB subtype, not DEL. FISH with
MYC
rearrangement but without rearrangements of
BCL2
or
BCL6
. Relapsed 1 year after CR w/R-CHOP. Progressed after clinical trial w/IV glofitamab. What would you next recommend?
A. Loncastuximab tesirine
B. Bendamustine-rituximab
C. Lenalidomide-rituximab
D. Lisocabtagene maraleucel
The most common adverse event in clinical trials evaluating bispecific antibodies was:
A. Neuropathy
B. Cytokine release syndrome
C. Neurotoxicity
D. Neutropenia
Start
Powered by
QuestionPro
Loading...
close
drag_indicator
close
Yes
Cancel
Continue
Answer Question
Continue Without Answering
Keep Data
Discard
close
drag_indicator
highlight_off